CARGO Therapeutics Inc CRGX.OQ CRGX.O is expected to show no change in quarterly revenue when it reports results for the period ending June 30 2025
LSEG's mean analyst estimate for CARGO Therapeutics Inc is for a loss of 67 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 4.4% in the last three months.
Wall Street's median 12-month price target for CARGO Therapeutics Inc is $5.50, above its last closing price of $4.02.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.57 | -0.72 | -1.77 | Missed | -144.1 |
Dec. 31 2025 | -0.94 | -0.96 | -0.95 | Beat | 1.2 |
Sep. 30 2024 | -1.10 | -1.13 | -0.88 | Beat | 22.2 |
Jun. 30 2024 | -1.01 | -1.03 | -1.02 | Beat | 0.7 |
Mar. 31 2024 | -1.06 | -1.05 | -0.87 | Beat | 17.4 |
Dec. 31 2023 | -1.44 | -1.44 | -1.49 | Missed | -3.2 |
Sep. 30 2023 | -2.78 | -2.78 | -47.37 | Missed | -1,601.9 |
This summary was machine generated May 10 at 00:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)